Small-Cap REIT ETF ...
Health Care: Drugs
Celgene Corporation (CELG: NASDAQ)
$124.91 1.43 | 1.16%
05/17/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with CELG
- Portfolio NameUser Type
- Userdennis all star
- Userportfolio 1.1
- UserCraigMcIlquham
- User4 Overvalued Biotechs
- ProRay Dalio - Bridgewater Ass...
- ProBill Miller - Legg Mason Ca...
- ContributorStocks Rising On Unusual Vo...
- UserTest Portfolio
- UserMike Fatah's Mega Stock Por...
- User2012 Allocation
Latest CELG Headlines from TheStreet
- Celgene Corporation (CELG): Today's Featured Health Care Winner 05.17.13 | 05:05 pm
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward 05.16.13 | 01:05 pm
- Cramer's 'Mad Money' Recap: Stick With What Works 05.14.13 | 08:05 pm
- Celgene Stock Hits New 52-Week High (CELG) 05.13.13 | 10:05 am
- Celgene Corporation (CELG): Today's Featured Drugs Winner 05.10.13 | 05:05 pm
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- 5 Stocks Advancing The Drugs Industry 05.07.13 | 01:05 pm
- Celgene Corporation (CELG): Today's Featured Drugs Winner 05.03.13 | 05:05 pm
- BMY, CELG And AMGN, 3 Drugs Stocks Pushing The Industry Lower 04.29.13 | 01:04 pm
- 'Mad Money' Lightning Round: Sell Dell ASAP 04.27.13 | 06:04 am
Press Releases for CELG
- Celgene Corporation To Webcast At Two Upcoming Investor Conferences And The American Academy Of Dermatology Annual Meeting - Business Wire 02.28.13 | 08:02 am
- Celgene Announces $600 Million Accelerated Share Repurchase Program - Business Wire 02.20.13 | 08:02 am
- Celgene Provides REVLIMID® Regulatory Update - Business Wire 02.11.13 | 07:02 am
- POMALYST(R) Brand Therapy (Photo: Business Wire) - Business Wire 02.08.13 | 03:02 pm
- Celgene Corporation To Webcast At Upcoming Investor Conferences - Business Wire 02.04.13 | 08:02 am
- Celgene Reports Strong Fourth Quarter And Full Year 2012 Operating And Financial Results - Business Wire 01.24.13 | 07:01 am
- The True Effect: Positive Findings - Research Report On Celgene Corporation And Gilead Sciences, Inc. - PR Newswire 01.23.13 | 08:01 am
- ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage In Phase III Study Of Patients With Advanced Pancreatic Cancer - Business Wire 01.22.13 | 06:01 pm
- Celgene Corporation Announces Financial Outlook And Preliminary 2012 Results - Business Wire 01.07.13 | 11:01 am
- Celgene Corporation To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.21.12 | 08:12 am
Partner Headlines for CELG
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks On The Move Table Identifies Emerging Leaders - Investor's Business Daily 04.10.13 | 05:04 pm
- How The IBD 50 Can Help Investors Find Winning Stocks - Investor's Business Daily 04.05.13 | 04:04 pm
- Stocks Open Sharply Lower After Employment Report - Investor's Business Daily 04.05.13 | 10:04 am
- Benzinga's Top Upgrades - Benzinga 04.05.13 | 08:04 am
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Top Funds' New Buys: Lumber Liquidators, Celgene - Investor's Business Daily 04.02.13 | 06:04 pm
- U.S. Mutual Funds Up 10% In Q1; Managers' Top Buys - Investor's Business Daily 04.02.13 | 06:04 pm
